RAG
发表于 2025-4-1 02:24:47
http://reply.papertrans.cn/83/8270/826986/826986_61.png
臆断
发表于 2025-4-1 08:26:41
Anti-VEGF and VEGFR Monoclonal Antibodies in RCC,women [.]. Its management has undergone a transformation in the past few years: novel targeted therapies have expanded considerably for patients with metastatic renal cell carcinoma (mRCC). Previously, systemic treatment was limited to cytokine therapy with interleukin (IL)-2 or interferon (IFN)-alp